Clinical trial
Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
NCT00169000 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00169000 |
|---|---|
| Title | Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers |
| Official title | Phase I Study of a Novel Schedule of Capecitabine and Docetaxel in Patients With Advanced Solid Tumors |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Docetaxel |
| Enrollment | 12 |
| Start date | Jan 1, 2003 |
| Primary completion | Sep 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 6, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: